DK21084A - Fremgangsmaade til fremstilling af et protein i en vaertscellekultur, dna-sekvens der koder for et dhfr-protein vektor for dna-sekvensen og vektor for denne og en anden dna-sekvens der koder for proteinet og selektering af transficerede eukaryotiske celler - Google Patents

Fremgangsmaade til fremstilling af et protein i en vaertscellekultur, dna-sekvens der koder for et dhfr-protein vektor for dna-sekvensen og vektor for denne og en anden dna-sekvens der koder for proteinet og selektering af transficerede eukaryotiske celler Download PDF

Info

Publication number
DK21084A
DK21084A DK21084A DK21084A DK21084A DK 21084 A DK21084 A DK 21084A DK 21084 A DK21084 A DK 21084A DK 21084 A DK21084 A DK 21084A DK 21084 A DK21084 A DK 21084A
Authority
DK
Denmark
Prior art keywords
dna sequence
protein
vector
transfer
selecting
Prior art date
Application number
DK21084A
Other languages
English (en)
Other versions
DK21084D0 (da
Inventor
Arthur David Levinson
Christian Clinton Simonsen
Elizabeth Mcleod Yelverton
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK21084D0 publication Critical patent/DK21084D0/da
Publication of DK21084A publication Critical patent/DK21084A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DK21084A 1983-01-19 1984-01-18 Fremgangsmaade til fremstilling af et protein i en vaertscellekultur, dna-sekvens der koder for et dhfr-protein vektor for dna-sekvensen og vektor for denne og en anden dna-sekvens der koder for proteinet og selektering af transficerede eukaryotiske celler DK21084A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45915183A 1983-01-19 1983-01-19

Publications (2)

Publication Number Publication Date
DK21084D0 DK21084D0 (da) 1984-01-18
DK21084A true DK21084A (da) 1984-08-24

Family

ID=23823619

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21084A DK21084A (da) 1983-01-19 1984-01-18 Fremgangsmaade til fremstilling af et protein i en vaertscellekultur, dna-sekvens der koder for et dhfr-protein vektor for dna-sekvensen og vektor for denne og en anden dna-sekvens der koder for proteinet og selektering af transficerede eukaryotiske celler

Country Status (7)

Country Link
EP (1) EP0117060A3 (da)
JP (1) JPS59192089A (da)
KR (1) KR840007254A (da)
AU (1) AU2353384A (da)
DK (1) DK21084A (da)
ES (1) ES8600780A1 (da)
ZA (1) ZA84376B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004784A (en) * 1959-07-20 1961-10-17 Tubular Structures Corp Of Ame Coupling pin

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010002A (en) * 1983-01-19 1991-04-23 Genentech, Inc. Human t-PA production using vectors coding DHFR protein
US5011795A (en) * 1983-01-19 1991-04-30 Genentech, Inc. Human tPA production using vectors coding for DHFR protein
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4670399A (en) * 1983-01-31 1987-06-02 Stauffer Chemical Co. Hybrid plasmid with marker
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
EP0221955A4 (en) * 1985-05-01 1988-12-22 Genetics Inst HIGH LEVEL REINFORCEMENT AND EXPRESSION OF EXOGENER DNA.
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPH0714341B2 (ja) * 1985-11-20 1995-02-22 鐘淵化学工業株式会社 蛋白質の高生産株の取得方法
GB8607502D0 (en) * 1986-03-26 1986-04-30 Antibioticos Sa Penicillium chrysogenum
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP2585532B2 (ja) * 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法
JPS63105675A (ja) * 1986-10-23 1988-05-10 Green Cross Corp:The ヒトウロキナ−ゼの製造方法
US5017478A (en) * 1987-07-16 1991-05-21 Berlex Laboratories, Inc. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
DE69231676T2 (de) * 1991-03-29 2001-05-17 Genentech Inc Methoden zur selektion von rekombinanten wirtszellen welche hohe mengen von einem gewünschten protein exprimieren
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
JP3394540B2 (ja) 1997-01-31 2003-04-07 ジェネンテク・インコーポレイテッド Ｏ−フコシルトランスフェラーゼ
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU739350B2 (en) 1997-06-05 2001-10-11 University Of Texas System, The APAF-1, the CED-4 human homolog, an activator of caspase-3
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
JP2001522584A (ja) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Ａｐｏ−３リガンドポリペプチド
EP2033970A3 (en) 1997-10-29 2009-06-17 Genentech, Inc. Polypeptides and nucleic acids encoding the same
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
ES2305608T3 (es) 1997-11-21 2008-11-01 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
JP5456222B2 (ja) 1998-12-23 2014-03-26 ジェネンテック， インコーポレイテッド Ｉｌ−１関連ポリペプチド
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
KR100674528B1 (ko) 1999-06-28 2007-01-29 제넨테크, 인크. 2가 금속 이온을 사용한 Ａｐｏ-2 리간드 제조 방법
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
EP2290081A3 (en) 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
EP1246917B1 (en) 2000-01-13 2009-03-04 Genentech, Inc. Human stra6 polypeptides
DK1255558T3 (da) 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
CA2403842C (en) 2000-03-24 2012-09-25 Genencor International, Inc. Increased production of secreted proteins by recombinant eukaryotic cells
EP2077276A1 (en) 2000-06-23 2009-07-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1992643A3 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1575338B (zh) 2001-08-29 2012-05-16 杰南技术公司 具有促细胞分裂活性的Bv8的核酸和多肽
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
EP1575571A4 (en) 2002-01-02 2008-06-25 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP2005528905A (ja) 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
AU2003237792A1 (en) 2003-04-01 2004-11-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
SI1641822T1 (sl) 2003-07-08 2013-08-30 Genentech, Inc. IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1689432B1 (en) 2003-11-17 2009-12-30 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
NZ551908A (en) 2004-07-26 2009-10-30 Genentech Inc Methods and compositions for modulating hepatocyte growth factor HGF activation
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ES2503365T5 (es) 2005-12-21 2017-10-31 Cnj Holdings, Inc Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
AU2013203482B2 (en) * 2006-09-10 2015-08-27 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
ES2620261T3 (es) * 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
CA2683423C (en) 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
EP2326720B1 (en) 2008-09-15 2018-03-21 F. Hoffmann-La Roche AG Compositions and methods for regulating cell osmolarity
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
AU2010236787A1 (en) 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
HUE048980T2 (hu) 2009-08-11 2020-08-28 Hoffmann La Roche Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
WO2011041308A1 (en) 2009-09-30 2011-04-07 Quest Diagnostics Investments Incorporated Bcr-abl truncation mutations
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
AR079217A1 (es) 2009-11-30 2012-01-04 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
MX2012009215A (es) 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103797026A (zh) 2010-09-15 2014-05-14 阿利吉那科技有限公司 由木质素衍生的化合物生物生产芳香族化学品
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
RU2014110953A (ru) 2011-08-22 2015-09-27 Гликотоп Гмбх Микроорганизмы, несущие опухолевый антиген
ES2784146T3 (es) 2011-10-21 2020-09-22 Pfizer Adición de hierro para mejorar el cultivo celular
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
PT2841087T (pt) 2012-04-27 2017-11-27 Us Health Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
AU2013348029A1 (en) 2012-11-20 2015-07-02 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX proteins
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN115177759A (zh) 2013-11-15 2022-10-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
SI3701971T1 (sl) 2014-03-14 2023-01-31 Biomolecular Holdings LLC, Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo
EP3119876A1 (en) 2014-03-19 2017-01-25 Pfizer Inc. Method of cell culture
WO2016090546A1 (en) 2014-12-09 2016-06-16 Wentao Zhang Nbp158 and uses thereof
CA2975734A1 (en) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
ES2774011T3 (es) 2015-05-22 2020-07-16 CSL Behring Lengnau AG Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
BR112018013861A2 (pt) 2016-01-07 2018-12-18 Csl Behring Recombinant Facility Ag polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
EP3196295A1 (en) 2016-01-25 2017-07-26 Albert-Ludwigs-Universität Freiburg Method of producing renal cells from fibroblasts
SG11201808356UA (en) 2016-04-05 2018-10-30 Pfizer Cell culture process
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
CA3074288A1 (en) * 2017-09-06 2019-03-14 Airway Therapeutics, LLC Methods, compositions and cells for preparing surfactant protein d (sp-d)
MA51676A (fr) 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
PT3743088T (pt) 2018-01-26 2022-12-05 Hoffmann La Roche Composições il-22 fc e métodos de utilização
MX2020008502A (es) 2018-02-21 2020-09-25 Genentech Inc Dosis para el tratamiento con proteinas de fusion il-22 fc.
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody
CA3121884A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4670399A (en) * 1983-01-31 1987-06-02 Stauffer Chemical Co. Hybrid plasmid with marker

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004784A (en) * 1959-07-20 1961-10-17 Tubular Structures Corp Of Ame Coupling pin

Also Published As

Publication number Publication date
KR840007254A (ko) 1984-12-06
EP0117060A2 (en) 1984-08-29
ES529021A0 (es) 1985-11-01
ZA84376B (en) 1985-02-27
ES8600780A1 (es) 1985-11-01
DK21084D0 (da) 1984-01-18
AU2353384A (en) 1984-07-26
EP0117060A3 (en) 1986-05-14
JPS59192089A (ja) 1984-10-31

Similar Documents

Publication Publication Date Title
DK21084A (da) Fremgangsmaade til fremstilling af et protein i en vaertscellekultur, dna-sekvens der koder for et dhfr-protein vektor for dna-sekvensen og vektor for denne og en anden dna-sekvens der koder for proteinet og selektering af transficerede eukaryotiske celler
DE3668186D1 (de) Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
NO831637L (no) System og metode for celleutvalg.
DK473987A (da) Fremgangsmaade til kontinuert produktion af et oensket heterologt protein i en eukaryotisk vaertcelle, vektor, som tilfoerer denne evne, og celler transformeret med vektoren
DE3377363D1 (en) Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
DK131988A (da) Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
DK638389A (da) Transformerende vaekstfaktor-beta2 og forstadier derfor, fremgangsmaade til deres fremstilling, nucleotidsekvens som koder derfor samt eukaryotiske celler og cellelinier indeholdende denne
DK0653242T3 (da) Katalysatorer, fremgangsmåde, i hvilken de anvendes, og fremgangsmåde til fremstilling af disse katalysatorer
DK4387D0 (da) Human-praepo-insulinlignende-vaerkstfaktor i samt gener og syntetiske dna-sekvenser, som koder for denne
DK54184A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human (interleukin) to-lignende polypeptider
DE3482045D1 (de) Dna sequenz in streptomyzinen.
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
NO845132L (no) Humant interferon-ypsilon-polypeptidderivat, fremgangsmaate for fremstilling derav og rekombinant plasmid inneholdende et dna-fragment som koder for polypeptidet
DE68911297D1 (de) Heparin bindende proteine, dafür kodierende dna, verfahren zu ihrer herstellung sowie sie enthaltende therapeutische präparate.
DK366589A (da) Humant protein c-mutant, dens fremstilling og dna, som koder derfor
NO842682L (no) Polypeptid og dna-sekvens samt vektor
DK447083A (da) Dna, som koder for humant interferon-gamma, rekombinant-dna indeholdende denne dna, mikroorganisme indeholdende rekombinant-dna'en og fremgangsmaade til fremstilling af humant interferon-gamma-polypeptid
DK151788A (da) Hybridserpiner og dna, som koder derfor
DE3581939D1 (de) Verfahren zum prozessorsteuerkodespeichern, das kodeveraenderung zulaesst und adressierschaltung dafuer.
DE3777723D1 (de) Nukleotidsequenz eines gens, das von einem insulinom exprimiert wird, und das davon kodierte protein.
NO862613L (no) Nye polypeptider med vekstfaktoraktivitet og nukleinsyresekvenser som koder for polypeptidene.
DK432285D0 (da) Fremgangsmaade til kloning af endogent modificeret streptomycetes-dna i restriktionsloese hetero-specifikke vaertsceller
DK370186D0 (da) Kloningsvehikel til kloning af et stort dna-fragment og en vaccine indeholdende 987p fimbrielt protein
DK440387D0 (da) Fremgangsmaade til udvaelgelse af streptomyces-vaertsceller og andre vaertsceller indeholdende rekombinant dna
DK494084D0 (da) Hybridoma, monokloniske antistoffer frembragt hermed og diagnosemetode under anvendelse af disse

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment